GSK Egypt logs 4123% YoY consolidated profit surge in 6 months
Updated 8/31/2022 10:21:00 AM
Arab Finance: GlaxoSmithKline (GSK – Egypt) (BIOC) registered a 4123% year-on-year increase in consolidated profit attributable to the parent company during the first six months of 2022, according to a financial statement filed to the Egyptian Exchange (EGX) on Wednesday.
The company’s consolidated profit excluding minority interest soared to EGP 871.808 million in the six-month period ended June 30th from EGP 20.644 million in the same period a year earlier.
Net sales jumped to EGP 716.78 million in the January-June period from EGP 406.846 million the year before.
GSK Egypt, a member of the British pharmaceutical company Glaxo Group, is an Egypt-based company engaged in the manufacturing, packaging, marketing, selling, and distribution of pharmaceutical products.
